Product image of Melphalan Aspen (Melphalan) supplied by GNH India

Melphalan Aspen

Active Ingredient:
Melphalan
Origin:
EU

Melphalan Aspen (Melphalan)

Melphalan, the active ingredient in Melphalan Aspen, is an alkylating agent presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic and solid tumors, including multiple myeloma, ovarian cancer, melanoma and cervical cancer.

GNH India supplies Melphalan Aspen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to hospitals, pharmacies and clinical trial sites across multiple regions. All shipments are accompanied by full documentation to ensure compliance with local import requirements.

Manufacturer / TM Owner

Aspen Pharma Trading Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melphalan is used as an antineoplastic agent targeting rapidly dividing cells in several cancer types.

  • Multiple myeloma: Reduces tumor burden and prolongs survival in patients with this plasma‑cell malignancy.
  • Ovarian cancer: Used in combination regimens to improve response rates in advanced disease.
  • Melanoma: Provides cytotoxic activity against metastatic lesions resistant to other therapies.
  • Cervical cancer: Contributes to tumor control when incorporated into multimodal treatment protocols.

How It Works

  • Melphalan exerts its antineoplastic effect by alkylating the N7 position of guanine bases in DNA. This creates intra‑ and interstrand cross‑links that impede DNA replication and transcription, ultimately triggering apoptosis in proliferating tumor cells. The irreversible DNA damage distinguishes it from reversible inhibitors and underlies its cytotoxic potency across a range of solid and hematologic malignancies.

Side Effects

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea and vomiting: Gastrointestinal upset commonly reported during treatment.
  • Fatigue: Generalized tiredness affecting daily activities.
  • Myelosuppression: Decreased blood cell counts leading to anemia or infection risk.
  • Alopecia: Temporary hair loss on scalp and body.
  • Mucositis: Inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects

  • Secondary malignancies: Development of new cancers after prolonged exposure.
  • Severe neutropenia: Marked reduction in neutrophils increasing infection susceptibility.
  • Pulmonary fibrosis: Scarring of lung tissue causing respiratory impairment.
  • Renal toxicity: Impaired kidney function manifesting as elevated creatinine.

Precautions & Warnings

When prescribing Melphalan, clinicians should observe several safety measures to minimize risks.

  • Baseline blood work: Obtain complete blood count and renal function before initiating therapy.
  • Monitor hematology: Perform regular CBCs to detect myelosuppression early.
  • Adjust for renal impairment: Reduce dose or increase interval in patients with decreased kidney function.
  • Avoid in active infection: Defer treatment until infection is controlled.
  • Counsel on contraception: Advise effective birth control during treatment and for a defined period after.
  • Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and light.

Avoid Interactions

Melphalan can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid)

  • CYP450 inducers: Drugs such as rifampin may lower melphalan plasma levels, reducing effectiveness.
  • High‑dose folate antagonists: Concurrent use can exacerbate myelosuppression.

Moderate Interactions (Monitor Closely)

  • Antiemetics containing steroids: May affect melphalan metabolism and increase infection risk.
  • NSAIDs: Can potentiate renal toxicity when combined with melphalan.
  • Live vaccines: Immunosuppression from melphalan may increase risk of vaccine‑derived infection.
  • Anticoagulants: Enhanced bleeding risk due to possible platelet count reductions.

Frequently Asked Questions

Melphalan Aspen is an oral antineoplastic medication indicated for the treatment of multiple myeloma, ovarian cancer, melanoma and cervical cancer. It belongs to the alkylating agent class and works by damaging DNA in rapidly dividing cancer cells.

Melphalan acts by alkylating the N7 position of guanine residues in DNA, forming intra‑ and interstrand cross‑links. These cross‑links block DNA replication and transcription, leading to apoptosis of malignant cells while sparing most normal tissues.

The dose of Melphalan Aspen is individualized by the prescribing physician based on factors such as the specific cancer type, disease stage, patient weight, renal function and prior treatment history. No fixed regimen is provided here.

Melphalan is classified as potentially harmful to the fetus and is generally contraindicated during pregnancy. It may also be excreted in breast milk, so breastfeeding is not recommended while receiving treatment. Consultation with a specialist is essential.

To request Melphalan Aspen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to alkylating agents but differs in its oral formulation and specific activity profile. Compared with agents such as cyclophosphamide, melphalan often shows higher potency in certain hematologic malignancies, though toxicity patterns may vary.

Store Melphalan Aspen tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and avoid crushing or splitting tablets unless directed by a pharmacist.

Melphalan Aspen is taken orally, usually with a glass of water. The exact timing relative to meals and any required pre‑medication (e.g., anti‑emetics) should follow the prescribing clinician’s instructions.

The most critical risks include severe myelosuppression leading to infection or bleeding, secondary malignancies arising after prolonged exposure, and organ toxicities such as pulmonary fibrosis and renal impairment. Patients should be monitored closely for these events.

Melphalan Aspen is contraindicated in patients with known hypersensitivity to melphalan or other alkylating agents, those with active uncontrolled infections, and individuals with severe renal impairment unless dose adjustments are made. Pregnant or nursing women should also avoid use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Melphalan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT